CA-PTW
4.2.2020 18:02:10 CET | Business Wire | Press release
PTW , the industry-leading video games and tech services outsourcer, today announced the appointment of Kasturi Rangan and Andy Emery to their C-Suite.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005364/en/
Andy Emery has been with PTW for five years and is stepping into the role of Chief Operating Officer. Andy joined PTW in 2015 through the acquisition of his company SIDE, which transformed PTW’s audio line of business. In 1997, Andy founded SIDE in London along with Phil Evans and Steve Parker with the mission of bringing world class voice performances to video game productions. SIDE found great success in that mission, working on many of the industries’ best loved franchises and being recognized with ten Industry Excellence Awards along the way. SIDE was acquired by PTW in 2015 and Andy became an integral part of the PTW executive team. Initially, Andy oversaw the opening of two new SIDE locations, in Los Angeles and Shanghai and became Vice President of Strategy and Innovation. His most recent role included managing the entire European region as President of Europe for PTW.
“PTW is thrilled to have Andy as a part of our executive team,” said Deborah Kirkham, CEO of PTW. “Andy is immensely creative and is also a force for reason in a complex, and often disorderly, global business landscape. His broad industry and entrepreneurial experience is particularly unique, and we benefit from his vision and depth of expertise daily. We’re honored to welcome him to the C-Suite and look forward to his continued contributions to PTW.”
Kasturi Rangan joins Andy in his appointment to the C-Suite, advancing to the role of Chief Product Officer. Rangan has been an integral part of PTW for nearly a decade, significantly growing and leading operations across the Quality Assurance, Innovation, and the Customer Experience line of business. In his most recent role at PTW, Rangan was the Regional President, leading the North American and India operations. He was also recently appointed as the CEO of PTW’s new game and product development brand, Orange Rock Studios. In his role as CPO of PTW, Rangan will oversee the product innovation and transformation arm for PTW globally.
“The best CPOs are visionaries of the future and evangelists for great product; Rangan is both. Rangan is the voice of innovation and a power for disruption at PTW; he is the natural choice as our CPO, and I welcome Rangan to the C-Suite,” said Deborah Kirkham.
Kirkham concluded, “With these two new appointments, PTW is now poised to move into a bright and successful future. Rangan and Andy bring very different and necessary voices to our team of leaders and we are already working together to build the future of PTW and the future of gaming.”
About PTW*
PTW is a leading games, digital entertainment and interactive media solutions provider with 16 offices in 10 countries worldwide. Our range of services include quality assurance, localization, customer experience, engineering and development services, and audio production services. PTW brings 25 years’ experience and the infrastructure to create customized support for projects and clients of all sizes.
PTW, comprised of global subsidiaries, is a UK-based holding company formed in 2016 under the umbrella of Poletowin Pitcrew Holdings, Inc. which is listed on the 1st Section of Tokyo Stock Exchange as 3657. POLE TO WIN is a registered trademark of Pole To Win Co., Ltd. in Japan and other countries. All rights reserved. For more information, visit https://www.ptw.com/
*Pole To Win International is now “PTW”
Stay connected with PTW on Facebook , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom